Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.

(RTTNews) - Novo Nordisk and Evotec have selected three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center for development ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

Novo Nordisk should deliver a 24% CAGR over two years, driven by robust obesity drug market growth and improved operational performance, with an intrinsic value implying a 29% safety margin.

Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture ...